Clinical Trial Update: A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) [Phase 1]

View source ↗

Summary

This is a Phase 1 study update of belzutifan (MK-6482) in participants with advanced clear cell renal cell carcinoma. The trial is currently active and not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Welireg (Belzutifan) (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: ACTIVE_NOT_RECRUITING